NCT05543928终止3 期
A Multi-Center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CTAP101 Extended-release Capsules to Treat Secondary Hyperparathyroidism in Pediatric Subjects of Ages 8 to <18 Years With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Numbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline
研究概览
简要总结
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled study in children with stage 3-4 chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and vitamin D insufficiency.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 8 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cohort 1: Be 12 to <18 years of age and have a body weight of ≥40 kg; Cohort 2: be 8 to <12 years of age and have a body weight of ≥20 kg.
- •Be diagnosed with stage 3 to 4 CKD at least six months prior to the screening visit, and have an eGFR of ≥15 to <60 mL/min/1.73m2 at screening.
- •Be without any disease state or physical condition that might impair evaluation of safety or which, in the investigator's opinion, would interfere with study participation, including:
- •Serum albumin ≤ 3.0 g/dL;
- •Serum transaminase (ALT or SGPT, AST or SGOT) > 2.5 times the upper limit of normal at screening; and,
- •Urinary albumin excretion of >3000 mcg/mg creatinine.
- •Exhibit during the initial or, if necessary, a screening visit after washout:
- •Plasma iPTH >100 pg/mL (stage 3 CKD) or >160 pg/mL (stage 4 CKD)
- •Serum calcium <9.8 mg/dL (corrected for albumin);
- •Serum total 25-hydroxyvitamin D <30 ng/mL; and,
- •Serum phosphorus >2.5 to ≤5.5 mg/dL (12 to <18 years) or ≤6.0 mg/dL (ages 8 to <12 years).
- •If taking calcitriol or other 1α-hydroxylated vitamin D analogs, or cinacalcet, be willing to forgo treatment with these agents for the duration of the study and complete an 8-week washout period prior to commencing treatment in the study.
- •If taking >1,000 mg/day of elemental calcium, discontinue or reduce calcium use and/or use non-calcium based therapies for the duration of the study.
- •If receiving ≤1,700 IU/day nutritional vitamin D (ergocalciferol or cholecalciferol) therapy, must agree to remain on a stable dose during the study.
- •If taking >1,700 IU/day of nutritional vitamin D, must discontinue or decrease the dose to ≤1,700 IU/day, maintain that dose for the duration of the study, and complete an 8-week washout period prior to commencing treatment in the study provided that serum total 25-hydroxyvitamin D is ≥30 ng/mL. The washout period is not necessary if serum total 25-hydroxyvitamin D is <30 ng/mL.
- •If taking any bone modifying treatment that could interfere with study endpoints, must discontinue use of such agent(s) for the duration of the study.
- •Willing and able to comply with study instructions and commit to all clinic visits for the duration of the study.
- •Female subjects of childbearing potential must be neither pregnant nor lactating and must have a negative urine pregnancy test at the first screening visit.
- •All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study.
- •Each subject or their legal representative must be able to read, understand and sign the informed consent form (ICF).
排除标准
- •History of or planned kidney transplant or parathyroidectomy.
- •History (prior three months) of serum calcium ≥9.8 mg/dL.
- •Use of bisphosphonate therapy (denosumab) within six months prior to enrollment.
- •Known previous or concomitant serious illness or medical condition, such as malignancy, human immunodeficiency virus, significant gastrointestinal or hepatic disease or cardiovascular event or hepatitis, or physical condition that in the opinion of the investigator may worsen and/or interfere with participation in the study.
- •History of neurological/psychiatric disorder, including psychotic disorder, or any reason which, in the opinion of the investigator makes adherence to a treatment or follow up schedule unlikely.
- •Known or suspected hypersensitivity to any of the constituents of either investigational product.
- •Currently participating in, or has participated in, an interventional/investigational study within 30 days prior to study screening.
研究组 & 干预措施
Cohort 1 and Cohort 2 Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Cohort 1 and Cohort 2 CTAP101 Capsule
Experimental
干预措施: CTAP101 (Drug)
结局指标
主要结局
Numbers of Subjects Who Attained Mean Decrease in Plasma iPTH of 30% From Baseline
时间窗: 26 weeks
The primary efficacy endpoint is the proportion of subjects in the intent-to- treat (ITT) population (age 8 to \<18 years) attaining a mean decrease in plasma iPTH of at least 30% from pre-treatment baseline compared to placebo during the EAP.
Safety and Tolerability
时间窗: 26 weeks
Safety and tolerability will be evaluated in the safety population by AEs, PEs, VS, hematology and laboratory evaluations, and ECGs.
Pharmacokinetic
时间窗: 26 weeks
To assess the pharmacokinetic (PK) profile of 25-hydroxyvitamin D3 after repeated doses of CTAP101 Capsules in pediatric subjects
次要结局
- Level of Serum Total 25-hydroxyvitamin D at ≥30 ng/mL Compared to Placebo(26 weeks)
- Plasma iPTH Mean Absolute Changes and Serum Total 25-hydroxyvitamin D(26 weeks)
- Pharmacodynamic Effects of Repeated Doses of CTAP101 Capsules(26 weeks)
- Incidence of Hypercalcemia and Hyperphosphatemia(26 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study of Efficacy and Safety of TLL-018 in CSU ParticipantsChronic Spontaneous UrticariaNCT06396026Hangzhou Highlightll Pharmaceutical Co., Ltd440
已完成
3 期
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia AreataAlopecia AreataNCT05051761Suzhou Zelgen Biopharmaceuticals Co.,Ltd425
已完成
3 期
Beraprost-314d Added-on to Tyvaso® (BEAT)Pulmonary Arterial HypertensionNCT01908699Lung Biotechnology PBC273
终止
3 期
The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive DisorderMajor Depressive DisorderNCT03487198Otsuka Beijing Research Institute65
已完成
3 期
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced PneumoniaCytokine Release Syndrome (CRS) in Patients With COVID-19-induced PneumoniaNCT04362813Novartis Pharmaceuticals454